Abstract

Non-ischemic cardiomyopathy (NICM) can cause left ventricular dysfunction through interstitial fibrosis, which corresponds to the failure of cardiac tissue remodeling. Recent evidence implicates monocytes/macrophages in the etiopathology of cardiac fibrosis, but giving their heterogeneity and the antagonizing roles of macrophage subtypes in fibrosis, targeting these cells has been challenging. Here we focus on WWP2, an E3 ubiquitin ligase that acts as a positive genetic regulator of human and murine cardiac fibrosis, and show that myeloid specific deletion of WWP2 reduces cardiac fibrosis in hypertension-induced NICM. By using single cell RNA sequencing analysis of immune cells in the same model, we establish the functional heterogeneity of macrophages and define an early pro-fibrogenic phase of NICM that is driven by Ccl5-expressing Ly6chigh monocytes. Among cardiac macrophage subtypes, WWP2 dysfunction primarily affects Ly6chigh monocytes via modulating Ccl5, and consequentially macrophage infiltration and activation, which contributes to reduced myofibroblast trans-differentiation. WWP2 interacts with transcription factor IRF7, promoting its non-degradative mono-ubiquitination, nuclear translocation and transcriptional activity, leading to upregulation of Ccl5 at transcriptional level. We identify a pro-fibrogenic macrophage subtype in non-ischemic cardiomyopathy, and demonstrate that WWP2 is a key regulator of IRF7-mediated Ccl5/Ly6chigh monocyte axis in heart fibrosis.

Non-ischemic cardiomyopathy is a severe disease, characterized by interstitial fibrosis in the left ventricle of the heart. Here authors show that the E3 ubiquitin ligase WWP2 plays a pathogenic role in heart fibrosis via regulating a distinct monocyte population that initiates the process.

Details

Title
The E3 ubiquitin ligase WWP2 regulates pro-fibrogenic monocyte infiltration and activity in heart fibrosis
Author
Chen, Huimei 1   VIAFID ORCID Logo  ; Chew, Gabriel 2 ; Devapragash, Nithya 2 ; Loh, Jui Zhi 2 ; Huang, Kevin Y. 2 ; Guo, Jing 2 ; Liu, Shiyang 2 ; Tan, Elisabeth Li Sa 2 ; Chen, Shuang 3 ; Tee, Nicole Gui Zhen 4 ; Mia, Masum M. 2 ; Singh, Manvendra K. 2   VIAFID ORCID Logo  ; Zhang, Aihua 5 ; Behmoaras, Jacques 6   VIAFID ORCID Logo  ; Petretto, Enrico 1   VIAFID ORCID Logo 

 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); China Pharmaceutical University, Institute for Big Data and Artificial Intelligence in Medicine, School of Science, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924) 
 China Pharmaceutical University, Institute for Big Data and Artificial Intelligence in Medicine, School of Science, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Children’s Hospital of Nanjing Medical University, Department of Nephrology, Nanjing, China (GRID:grid.452511.6) 
 National Heart Centre Singapore, Singapore, Singapore (GRID:grid.419385.2) (ISNI:0000 0004 0620 9905) 
 Children’s Hospital of Nanjing Medical University, Department of Nephrology, Nanjing, China (GRID:grid.452511.6) 
 Duke-NUS Medical School, Programme in Cardiovascular and Metabolic Disorders, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Imperial College London, Hammersmith Hospital, Centre for Inflammatory Disease, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2742910446
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.